Family Planning and Rheumatoid Arthritis
- 102 Downloads
Purpose of Review
Patients with rheumatoid arthritis (RA) have special family planning considerations that require close coordination with health care providers. While this article focuses on issues inherent to female patients given their potential for pregnancy, we will review pertinent issues related to medication counseling for male patients.
Some women with RA may experience subfertility. Disease activity may decrease for some, but not all pregnant women with RA. Preterm birth is more common among women with RA than among healthy women, which may be explained, in part, by disease activity and/or use of certain medications. Contraception is safe for women with RA.
RA is a chronic, female-predominant inflammatory disease that may affect women and men during their reproductive years. We describe some of these considerations herein and focus on strategies to help providers to clarify and support their patients’ reproductive goals.
KeywordsRheumatoid arthritis Women’s health Family planning Pregnancy
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 13.NCHS. Key statistics from the National Survey of Family Growth. In. Centers for Disease Control and Prevention: Atlanta; 2016.Google Scholar
- 15.• Brouwer J, Fleurbaaij R, Hazes JMW, Dolhain R, Laven JSE. Subfertility in women with rheumatoid arthritis and the outcome of fertility assessments. Arthritis Care Res (Hoboken). 2017;69(8):1142–9. While subfertility is an issue for some women with RA, this paper helps to demonstrate that assisted reproductive technologies are effective for these women. CrossRefGoogle Scholar
- 19.de Man YA, Bakker-Jonges LE, Goorbergh CM, Tillemans SP, Hooijkaas H, Hazes JM, et al. Women with rheumatoid arthritis negative for anti-cyclic citrullinated peptide and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody-positive women autoantibody levels are not influenced by pregnancy. Ann Rheum Dis. 2010;69(2):420–3.PubMedCrossRefGoogle Scholar
- 27.Smith CJF, Forger F, Bandoli G, Chambers CD. Factors associated with preterm delivery among women with rheumatoid arthritis and juvenile idiopathic arthritis. Arthritis Care Res. 2018.Google Scholar
- 28.Bharti B, Lee SJ, Lindsay SP, Wingard DL, Jones KL, Lemus H, et al. Disease severity and pregnancy outcomes in women with rheumatoid arthritis: results from the Organization of Teratology Information Specialists Autoimmune Diseases in pregnancy project. J Rheumatol. 2015;42(8):1376–82.PubMedCrossRefGoogle Scholar
- 31.Birru Talabi M, Clowse MEB, Blalock SJ, Moreland L, Siripong N, Borrero S. Contraception use among reproductive-age women with rheumatic diseases. Arthritis Care Res. 2018.Google Scholar
- 32.Daniels KDJ, Jones J. Current contraceptive status among women aged 15–44: United States, 2011–2013. In: NCHS Data Brief. Hyattsville: National Center for Health Statistics; 2015. p. 1–8.Google Scholar
- 34.U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force Recommendation Statement; Final Recommendations. Ann Intern Med. 151:716–26.Google Scholar
- 40.Curtis KJT, Tepper NK, Zapata L, Horton L, Jamieson DJ, Whiteman MK. U.S. Medical Eligibility Criteria for contraceptive use. In: Centers for Disease Control and Prevention: Morbidity and Mortality Weekly Report; 2016.Google Scholar
- 41.•• Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795–810. This is a very important set of guidelines to help providers weigh the risks and benefits of anti-rheumatic drug use in anticipation of or during pregnancy. Guidelines from the American College of Rheumatology are forthcoming in 2019. PubMedCrossRefGoogle Scholar
- 42.CDC. Effectiveness of family planning methods. 2018.Google Scholar
- 43.Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology. 2016;55(9):1693–7.PubMedCrossRefGoogle Scholar
- 44.•• Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. Rheumatology. 2016;55(9):1698–702. This is another important set of guidelines to help providers safely prescribe anti-rheumatic drugs before, during, or after pregnancy.PubMedCrossRefGoogle Scholar
- 46.Hays S. The cultural contradictions of motherhood. New Haven: Yale University Press; 1998.Google Scholar
- 47.Mother to Baby. https://mothertobaby.org.
- 68.Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, network of French pharmacovigilance c, Beghin D, et al. Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015;80(4):727–39.PubMedPubMedCentralCrossRefGoogle Scholar
- 69.• Vinet E, De Moura C, Pineau CA, Abrahamowicz M, Curtis JR, Bernatsky S. Serious Infections in rheumatoid arthritis offspring exposed to tumor necrosis factor inhibitors: a cohort study. Arthritis Rheumatol. 2018;70(10):1565–71. This study shows that infection risk is generally low among neonates exposed to TNF-alpha inhibitors in utero , although there may be an increased risk of infections from infliximab.PubMedCrossRefGoogle Scholar
- 71.Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476–85.PubMedPubMedCentralCrossRefGoogle Scholar
- 73.•• Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: a systematic review and analysis of published evidence. Semin Arthritis Rheum. 2018. This is one of the first reviews available to help providers to counsel men with rheumatic diseases about medications in anticipation of pregnancy. Google Scholar
- 84.Geist C, Aiken AR, Sanders JN, Everett BG, Myers K, Cason P, et al. Beyond intent: exploring the association of contraceptive choice with questions about pregnancy attitudes, timing and how important is pregnancy prevention (PATH) questions. Contraception. 2018.Google Scholar
- 86.Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, et al. Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res. 2015;67(3):313–25.CrossRefGoogle Scholar